Edwards Lifesciences Corporation (NYSE:EW) – Investment analysts at Leerink Swann raised their FY2019 earnings per share (EPS) estimates for shares of Edwards Lifesciences in a research report issued to clients and investors on Wednesday. Leerink Swann analyst D. Antalffy now anticipates that the medical research company will post earnings per share of $4.48 for the year, up from their previous estimate of $4.45. Leerink Swann also issued estimates for Edwards Lifesciences’ FY2020 earnings at $5.23 EPS and FY2021 earnings at $6.10 EPS.

Other research analysts have also issued reports about the company. Morgan Stanley dropped their price target on Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating on the stock in a research report on Thursday, October 26th. William Blair reissued an “outperform” rating on shares of Edwards Lifesciences in a research report on Monday, August 28th. Royal Bank Of Canada reissued a “buy” rating and set a $130.00 price target on shares of Edwards Lifesciences in a research report on Friday, September 1st. Canaccord Genuity reissued a “buy” rating and set a $155.00 price target on shares of Edwards Lifesciences in a research report on Sunday, October 8th. Finally, Barclays reissued an “equal weight” rating and set a $120.00 price target on shares of Edwards Lifesciences in a research report on Saturday, September 30th. Seven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $125.53.

Edwards Lifesciences (NYSE EW) opened at $116.41 on Friday. The firm has a market capitalization of $24,801.85, a price-to-earnings ratio of 32.47, a P/E/G ratio of 2.10 and a beta of 0.50. Edwards Lifesciences has a 52-week low of $81.25 and a 52-week high of $121.45. The company has a current ratio of 3.49, a quick ratio of 2.76 and a debt-to-equity ratio of 0.33.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the consensus estimate of $0.86 by ($0.02). The business had revenue of $821.50 million for the quarter, compared to analyst estimates of $833.85 million. Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The firm’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.68 earnings per share.

In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $100.93, for a total value of $3,320,597.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $116.45, for a total value of $617,185.00. The disclosure for this sale can be found here. Insiders sold 172,480 shares of company stock worth $18,548,810 in the last 90 days. Corporate insiders own 2.13% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. ETF Managers Group LLC bought a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $112,000. Shine Investment Advisory Services Inc. bought a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $126,000. MPS Loria Financial Planners LLC bought a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $140,000. Dupont Capital Management Corp bought a new stake in shares of Edwards Lifesciences during the 3rd quarter worth about $142,000. Finally, Captrust Financial Advisors bought a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $149,000. Hedge funds and other institutional investors own 81.55% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/12/02/edwards-lifesciences-corporation-ew-expected-to-post-fy2019-earnings-of-4-48-per-share.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.